RAS-Mutant Leukemia Stem Cells Drive Clinical Resistance to Venetoclax

Investigators provide the mechanistic explanation for this in a requirement for mutant RAS to specifically transform committed progenitors of the myelomonocytic lineage harboring previously acquired driver mutations, showing that advanced leukemic clones can originate from a different cell type in the hematopoietic hierarchy than ancestral clones.